Clinical Phenotypes and Glycopeptide Escalation Patterns in Pediatric Febrile Neutropenia: Associations with
Neryal Tahta1, Zuhal Önder Siviş1, Mehtap Ertekin1
1University of Health Sciences Türkiye, İzmir City Hospital, Clinic of Pediatric Hematology Oncology, İzmir, Türkiye
Objective:
Febrile neutropenia (FN) in pediatric oncology is a clinically heterogeneous syndrome in which early antibiotic escalation decisions are frequently driven by non-specific severity cues. We aimed to identify baseline clinical phenotypes of pediatric FN, to describe early glycopeptide escalation patterns across these phenotypes, and to examine their associations with short-term outcomes and acute kidney injury (AKI).
Materials And Methods:
We conducted a retrospective cohort study including 106 FN episodes experienced by 82 pediatric oncology patients initially treated with piperacillin-tazobactam monotherapy. Baseline clinical and laboratory variables available within the first 6 hours of FN onset were used for unsupervised k-means clustering to derive latent clinical phenotypes. Early glycopeptide escalation was defined as the initiation of vancomycin or teicoplanin within 48 hours. Associations with clinical outcomes on day 7 and AKI were evaluated using multivariable cluster-robust regression and inverse probability of treatment weighting.
Results:
Three distinct FN phenotypes were identified: a high-inflammatory/mucositis-dominant phenotype (39.6%), a hemodynamically severe phenotype (22.6%), and a lower-severity phenotype (37.7%). Early glycopeptide escalation occurred in 26.4% of episodes and was disproportionately concentrated in the high-inflammatory and hemodynamically severe phenotypes. AKI developed in 10.4% of FN episodes and clustered predominantly within escalation-prone phenotypes. After adjustment, early escalation was not associated with improved day-7 clinical success but was associated with a higher observed risk of AKI.
Conclusion:
Pediatric FN comprises distinct clinical phenotypes that differentially drive antibiotic escalation behavior and renal injury risk. A phenotype-informed approach may help to optimize escalation decisions and potentially reduce preventable toxicity. However, given the observational design of this study, these associations should be interpreted with caution.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury III: Clinical Manifestations
Acute Pyelonephritis I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology


